Exhibit 107
Calculation of Filing Fee Table
Schedule TO-T
(Rule 14d-100)
MorphoSys AG
(Name of Subject Company)
Novartis AG
(Offeror – Name of Filing Person)
Table 1-Transaction Valuation
| Transaction Valuation* | Fee Rate | Amount of Filing Fee** | ||||||||||
| Fees to Be Paid | $ | 263,898,777 | 0.00014760 | $ | 38,951 | |||||||
| Fees Previously Paid | $ | 0 | $ | 0 | ||||||||
| Total Transaction Valuation | $ | 263,898,777 | ||||||||||
| Total Fees Due for Filing | $ | 38,951 | ||||||||||
| Total Fees Previously Paid | $ | 0 | ||||||||||
| Total Fee Offsets | $ | 0 | ||||||||||
| Net Fee Due | $ | 38,951 | ||||||||||
* The calculation of the transaction valuation assumes the purchase of no-par value bearer shares (each, a “MorphoSys Share”), of MorphoSys AG (“MorphoSys”), including those MorphoSys Shares represented by American Depositary Shares (“MorphoSys ADSs”) at a purchase price of €68.00 per MorphoSys Share in cash, converted into a purchase price of $72.83 per MorphoSys Share using a rate of 1.0711 U.S. dollars per 1.00 Euro, the noon buying rate as of June 28, 2024 published by the Federal Reserve Bank of New York. The calculation of the transaction valuation is determined by adding the sum of (i) 3,378,614 issued MorphoSys Shares (including MorphoSys Shares held by MorphoSys in treasury and excluding MorphoSys Shares held by Novartis BidCo Germany AG) and (ii) 244,876 additional MorphoSys Shares exercisable prior to the expiry of the three (3) month period following the publication of the Offer Document, multiplied by the offer consideration of $72.83 per MorphoSys Share.
** The filing fee was calculated in accordance with Rule 0-11 under the Exchange Act, and the Fee Rate Advisory for Fiscal Year 2024, issued August 25, 2023, by multiplying the transaction valuation by 0.00014760.